Nyrada Inc. (NYR.AX)
Nyrada Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Sydney, NSW, AU. The stock last traded at $0.76, down 1.94% on the session, giving a market capitalisation of $184.9M. Its beta of 0.93 implies it has historically moved less than the broad market.
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Nyrada Inc. is most often compared with the following Healthcare names: